Advances of the matrix assisted laser desorption ionization-time of flight-mass spectrometry in lung cancer

Abstract

Wang Zihe, Liu Xiaoqing. Advances of the matrix assisted laser desorption ionization-time of flight-mass spectrometry in lung cancer[J]. Journal of International Oncology, 2014, 41(5): 344-347.

［1］张鑫宇, 刘皈阳, 祝晓光, 等. 非小细胞肺癌EGFR突变的检测方法［J］. 中国肺癌杂志, 2011, 14(3):297-302. ［2］安娟, 汤传昊, 王娜, 等. MALDITOF质谱筛查NSCLC患者血清特异性多肽的探索性研究［J］. 中国肺癌杂志, 2013, 16(5): 233-239. ［3］李永文, 刘红雨, 李颖, 等. 实时荧光定量PCR和测序法检测非小细胞肺癌EGFR基因突变的比较［J］. 中国肺癌杂志, 2009, 12(12):1255-1259. ［4］ Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmallcell lung cancer［J］. J Clin Oncol, 2012, 30(4):433-440. ［5］ Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFRmutant nonsmall cell lung cancers［J］. Lung Cancer, 2007, 58(1):95-103. ［6］ Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib［J］. Clin Cancer Res, 2006, 12(19):5764-5769. ［7］杨拴盈, 田应选, 南岩东, 等. 应用液体芯片飞行时间质谱技术筛选血清中肺癌标志蛋白［J］. 西安交通大学学报(医学版), 2011, 32(1):17-11. ［8］陈晓, 刘良, 周华, 等. 全身多发转移与无转移非小细胞肺癌患者血浆蛋白组学比较分析［J］. 中国现代医学杂志, 2013, 23(27):30-34. ［9］ Brevet M, Johnson ML, Azzoli CG, et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors［J］. Lung Cancer, 2011, 73(1):96-102. ［10］ Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to Ⅳ nonsmallcell lung cancer［J］. J Clin Oncol, 2009, 27(16):2653-2659. ［11］秦楚, 王朝霞. 非小细胞肺癌个体化治疗研究进展［J］. 中华临床医师杂志(电子版)， 2013, 7(21):9681-9686. ［12］刘丽华, 孟君, 张璁, 等. 运用MALDITOF MS方法建立食管癌患者血清蛋白指纹图谱诊断模型［J］. 肿瘤防治研究, 2012, 39(2):169-172. ［13］ Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFRTKIs target treatment for patients with NSCLC［J］. Onco Targets Ther, 2013, 6:1481-1491. ［14］赵实诚, 许洋. 蛋白质指纹技术在临床医学的应用与研究进展［J］. 中华检验医学杂志, 2004, 27(10):706-709. ［15］刘丹, 刘伦旭, 袁泉, 等. 运用激光解析电离飞行时间质谱技术检测肺腺癌的血清蛋白表达［J］. 四川大学学报·医学版, 2010, 41(3):498-500. ［16］ Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumor subsets in nonsmall cell lung cancer［J］. Lancet, 2003, 362(9382):433-439. ［17］ Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma massspectral profile in course of treatment of nonsmall cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors［J］. J Thorac Oncol, 2012, 7(1):40-48. ［18］ Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients［J］. Cancer Epidemiol Biomarkers Prev, 2010, 19(2):358-365. ［19］郭帅, 李智立. 质谱成像及其在生物医学领域的应用［J］. 生物物理学报, 2011, 27(12):1008-1018. ［20］杨帆, 原剑, 郑俊杰, 等. MALDITOF生物质谱成像技术的进展［J］. 分析仪器, 2010, 3:1-8. ［21］ Shimma S, Sugiura Y, Hayasaka T, et al. MALDIbased imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis［J］. J Chromatogr B Analyt Biomed Life Sci, 2007, 855(1):98-103. ［22］ Altelaar AF, Taban IM, McDonnell LA, et al. Highresolution MALDI imaging mass spectrometry allows localization of peptide distributions at cellular length scales in pituitary tissue sections［J］. Int J Mass Spectrom, 2007, 260(2-3):203-211. ［23］张莹, 陈岚, 陆豪杰, 等. MALDI质谱成像技术在非小细胞肺癌中的应用研究［J］. 质谱学报, 2007, 28(4):209-213.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[3]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[4]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[5]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[6]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[7]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[8]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model[J]. Journal of International Oncology, 2022, 49(9): 532-536.
[9]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying.Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses[J]. Journal of International Oncology, 2022, 49(8): 459-463.
[10]	Cai Gangxiang, Li Jing, Xu Bin.Advances in neoadjuvant immunotherapy for lung cancer[J]. Journal of International Oncology, 2022, 49(6): 366-370.
[11]	Liu Xiaoting, Liu Yang, Zhang Huanqin, Xing Jinliang, Quan Zhibo.Application of tumor biomarkers in the diagnosis and prognosis of hepatocellular carcinoma[J]. Journal of International Oncology, 2022, 49(6): 371-375.
[12]	Zhang Jingxian, Yi Dan, Li Xiaojiang.Application of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(5): 296-301.
[13]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei.Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer[J]. Journal of International Oncology, 2022, 49(4): 247-251.
[14]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145.
[15]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming.Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 111-115.

Advances of the matrix assisted laser desorption ionization-time of flight-mass spectrometry in lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments